查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012717

動物抗菌胜肽市場：按產品類型、應用和最終用戶分類－2026-2032年全球市場預測

Animal Antibacterial Peptide Market by Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物抗菌肽市值將達到 46.9 億美元，到 2026 年將成長至 54.2 億美元，到 2032 年將達到 146.8 億美元，複合年成長率為 17.68%。

主要市場統計數據
基準年 2025 46.9億美元
預計年份：2026年 54.2億美元
預測年份 2032 146.8億美元
複合年成長率 (%) 17.68%

以科學進步、監管變化、相關人員獎勵和商業化的實際實施途徑為框架，對動物抗菌肽進行策略性展望。

隨著相關人員積極應對日益嚴重的抗生素抗藥性和不斷變化的法規環境，動物抗菌肽領域正迎來科學界和商業性日益關注的時期。基於胜肽的抗菌策略利用多種生物機制，具有特異性強、抗藥性選擇少、易於與綜合動物健康計畫相容等優勢。胜肽合成、製劑和標靶遞送技術的進步已使許多概念從科學概念驗證（PoC）階段邁向轉化開發階段，促使更多商業相關人員評估胜肽作為傳統抗生素的有效替代品或補充療法。因此，獸醫、飼料生產商、水產養殖經營者和生物技術公司正在重新評估治療方案、畜群健康經濟效益和產品定位，並對胜肽解決方案獨特的風險回報特徵有了清晰的認知。

本文詳細探討了由合成技術的突破、診斷技術的整合以及監管認可度的提高所驅動的，重塑動物抗菌肽開發的決定性變革。

動物抗菌肽領域正經歷變革性的轉變，技術、監管和市場催化因素共同推動這項變革，重塑競爭格局。在技​​術層面，合成技術的創新和純化製程的改進已基本消除了主要的製程瓶頸，使生產商能夠生產出具有更高保真度和針對特定需求客製化的理化性質的胜肽。同時，精準的診斷和病原體監測使得更有針對性的治療和預防干涉成為可能，從而提升了具有窄頻譜或物種特異性活性且對微生物組影響最小的產品的商業性價值。

重點評估美國於 2025 年實施的累積關稅措施將如何影響胜肽原料採購、契約製造決策和供應鏈彈性策略。

美國在2025年實施的關稅措施，加劇了動物抗菌胜肽研發和商業化企業對供應鏈的擔憂。由於胜肽的生產通常依賴特殊的原料、試劑和外包合成能力，關稅政策的變化會影響籌資策略以及全球和國內生產之間的競爭格局。先前依賴低成本海外供應商的企業正在重新評估其總到岸成本、前置作業時間和庫存策略，以降低關稅變化帶來的風險。在這些策略調整中，一些企業正在探索近岸外包，並建立冗餘的供應商網路，以維持生產的連續性，並更快地應對需求波動。

基於細分市場的全面洞察，將產品類型差異、應用管道和最終用戶人口統計特徵與需求、配方要求和市場進入管道選擇等經驗數據連結。

了解市場區隔對於設計符合客戶需求和技術可行性的產品系列和商業化路徑至關重要。從產品類型角度分析產品，可以發現天然胜肽和合成胜肽之間有顯著差異。此外，合成胜肽根據鍊長可細分為長鏈、中鍊和短鏈三類，每類胜肽的穩定性、效力和生產過程均有所不同。這些產品層面的特性會影響製劑選擇、給藥途徑和成本結構，從而指導企業應將製程開發和分析表徵工作重點放在哪些方面。

美洲、歐洲、中東和非洲以及亞太地區的區域商業化和監管前景決定了不同地區的採取路徑和戰略重點。

區域趨勢對動物抗菌肽領域的監管策略、商業化時機和投資重點有顯著影響。在美洲，監管機構和相關人員優先考慮合理使用抗菌藥物和切實降低對抗生素的依賴性，從而創造出以可證實的動物健康效果和經濟效益為導向的購買決策環境。該地區擁有眾多跨國動物用藥品公司和成熟的契約製造網路，這使得符合監管和臨床標準的候選藥物能夠快速擴大生產規模，但也加劇了獸醫和生產商之間的競爭。

競爭情報和企業創新資訊表明，成熟企業、生物技術創新者和製造專家如何合作推進胜肽候選藥物的開發和商業化。

動物抗菌肽領域的競爭格局呈現出複雜的創新生態系統，該生態系統由成熟的動物用藥品公司、新興生物技術公司、專業肽類藥物研發公司和契約製造組織組成。成熟的動物用藥品公司在監管合規、分銷網路和客戶關係方面具有優勢，當有證據支持其臨床和經濟價值時，可以將基於胜肽的產品整合到現有產品組合中。同時，小規模的生技公司和大學衍生公司往往是早期創新的驅動力，它們推動新型序列、遞送平台和作用機制的研發，挑戰著傳統的治療方法。

為產業領導者提供切實可行的策略建議，以加快證據產生、確保有韌性的供應鏈、儘早與監管機構接觸以及製定以最終用戶為中心的商業化策略。

產業領導者應優先實施一系列行動，以加速負責任地推廣應用，並在管控技術和商業性風險的同時，確保先發優勢。首先，投資於嚴謹、以結果為導向的證據生成，將受控臨床試驗與實際生產測試結合。這種雙管齊下的方法既能證明在理想條件下的療效，又能證明在實際運作環境中的可操作效益。其次，制定模組化製造策略，將內部關鍵品質屬性的製造能力與提供規模和冗餘的認證合約合作夥伴結合，從而降低供應風險和關稅相關的干擾。

我們透明的調查方法結合了結構化的相關人員訪談、技術文獻綜述、監管分析和跨來源檢驗，從而得出可靠且可操作的結論。

本分析整合了第一手和第二手研究、技術文獻綜述以及與相關人員的對話，旨在建立一個基於證據的動物抗菌肽應用觀點。第一手資料包括對獸醫、飼料負責人、契約製造和科研人員的結構化訪談，以將技術主張與實際操作相結合，並識別該領域面臨的應用障礙。第二手資料包括同行評審文獻、監管指導文件和專利申請，以了解技術發展軌跡和智慧財產權主題。此外，還進行了嚴格的篩檢，以避免依賴單一來源的商業性摘要。

綜合考慮技術潛力、商業化現實和策略路徑，可以指導有關動物抗菌肽的引進和投資的決策。

總之，動物抗菌肽是改善動物健康和生產永續性、同時減少對傳統抗生素依賴的更廣泛策略中一個極具前景且切實可行的組成部分。胜肽設計和遞送方面的科學進步，以及監管機構對替代療法更開放的態度，提高了基於胜肽的干涉措施的可行性。然而，商業化成功取決於嚴格的安全性和有效性證據、生產規模化能力以及適應不同終端用戶現有營運模式的能力。整合跨領域能力、尋求策略夥伴關係並採取完善的供應鏈和監管策略的組織將更有利於將科學潛力轉化為商業性影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物抗菌胜肽市場：依產品類型分類

  • 天然來源胜肽
  • 合成胜肽
    • 長鏈
    • 中鏈
    • 短鏈

第9章：動物抗菌胜肽市場：依應用領域分類

  • 促進生長
  • 預防
    • 疾病預防
    • 疫苗佐劑
  • 治療
    • 感染疾病治療
    • 皮膚病的治療

第10章：動物抗菌胜肽市場：依最終用戶分類

  • 水產養殖場
  • 飼料生產商
    • 水產飼料
    • 牲畜飼料
  • 研究機構
    • 學術機構
    • 生技公司
  • 動物醫院
    • 大型動物治療
    • 小動物治療

第11章：動物抗菌胜肽市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：動物抗菌胜肽市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：動物抗菌胜肽市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國動物用抗菌胜肽市場

第15章：中國動物用抗菌胜肽市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AB Vista Limited
  • AgroBioTek Laboratories LLC
  • Animal Medics
  • Anitox Corporation
  • Biogenesis Bago SA
  • Biosynth Ltd
  • Boehringer Ingelheim International GmbH
  • Cargill, Incorporated
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Ltd.
  • Elanco Animal Health Incorporated
  • Esco Aster Pte. Ltd.
  • Genera Inc.
  • Huvepharma SA
  • ImmuCell Corporation
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Novozymes A/S
  • Phibro Animal Health Corporation
  • Vetbiochem India Pvt Ltd.
  • Vetoquinol SA
  • Zoetis Inc.
  • Zomedica Pharmaceuticals Corp.
Product Code: MRR-4369010662C8

The Animal Antibacterial Peptide Market was valued at USD 4.69 billion in 2025 and is projected to grow to USD 5.42 billion in 2026, with a CAGR of 17.68%, reaching USD 14.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.69 billion
Estimated Year [2026] USD 5.42 billion
Forecast Year [2032] USD 14.68 billion
CAGR (%) 17.68%

A strategic orientation to animal antibacterial peptides that frames scientific advances, regulatory shifts, stakeholder incentives, and practical adoption pathways for commercialization

The animal antibacterial peptide space has entered a period of intensified scientific and commercial attention as stakeholders respond to rising antimicrobial resistance and shifting regulatory expectations. Peptide-based antimicrobial strategies draw on diverse biological mechanisms that offer specificity, reduced propensity for resistance selection, and compatibility with integrated animal health programs. Advances in peptide synthesis, formulation, and targeted delivery have moved many concepts from academic proof-of-concept to translational development, prompting a broader set of commercial actors to evaluate peptides as viable alternatives or complements to traditional antibiotics. As a result, veterinarians, feed formulators, aquaculture operators, and biotechnology firms are reassessing therapeutic protocols, herd health economics, and product positioning with a clearer appreciation for the unique risk-return profile of peptide solutions.

Transition from laboratory innovation to commercial readiness requires navigating scientific validation, manufacturing complexity, and regulatory alignment. The introduction of robust analytical methods and scalable synthesis platforms has reduced technical barriers, while simultaneous progress in adjuvant and delivery technologies has enhanced in vivo efficacy and stability. These converging trends create a window of opportunity for organizations that can integrate multidisciplinary capabilities, engage early with regulatory bodies, and design pragmatic evidence-generation strategies. Moving forward, success will hinge on translating mechanistic advantages into demonstrable animal health outcomes, operational compatibility, and commercial value propositions that resonate across diverse end users.

An in-depth exploration of the pivotal shifts reshaping animal antibacterial peptide development driven by synthesis breakthroughs, diagnostics integration, and evolving regulatory acceptance

The landscape for animal antibacterial peptides is undergoing transformative shifts driven by technological, regulatory, and market catalysts that are redefining competitive dynamics. On the technological front, synthesis innovations and improved purification processes have materially reduced key technical bottlenecks, enabling manufacturers to produce peptides with higher fidelity and tailored physicochemical properties. Concurrently, precision diagnostics and pathogen surveillance are enabling more targeted therapeutic and prophylactic interventions, which strengthens the commercial case for products that offer narrow-spectrum or species-specific activity and minimize microbiome disruption.

Regulatory attitudes are also evolving: authorities are increasingly receptive to antimicrobial alternatives that demonstrate clear animal welfare benefits and environmental advantages, provided that rigorous safety and efficacy data accompany submissions. This regulatory momentum incentivizes manufacturers to pursue structured evidence-generation programs that incorporate field trials and comparative effectiveness endpoints. In parallel, end users such as feed manufacturers and aquaculture producers are seeking solutions that integrate seamlessly with existing production systems, creating demand for formulations that are stable in feed matrices or water and deliver predictable dosing. These cumulative shifts favor organizations that adopt a systems-based approach, aligning R&D, manufacturing, and commercialization to reduce friction between product attributes and operational realities.

A focused assessment of how cumulative United States tariff measures enacted in 2025 influence peptide input sourcing, contract manufacturing decisions, and supply chain resilience strategies

United States tariff actions in 2025 have amplified supply chain considerations for organizations involved in animal antibacterial peptide development and commercialization. Because peptide production often depends on specialized raw materials, reagents, and outsourced synthesis capacity, changes in tariff policy influence procurement strategies and the relative competitiveness of global versus domestic manufacturing. Firms that previously relied on low-cost international suppliers are reassessing total landed cost, lead times, and inventory policies to mitigate exposure to tariff volatility. As these strategic adjustments occur, some organizations are exploring nearshoring or establishing redundant supplier networks to preserve continuity of production and accelerate response to demand fluctuations.

At the operational level, tariff-related cost pressures can affect decisions about vertical integration, contract manufacturing partnerships, and the location of high-value activities such as analytical testing and final formulation. Companies with flexible supply chains that can adapt sourcing, qualify alternate reagents, and adjust batch scheduling will be better positioned to absorb tariff-driven dislocations without compromising timelines for development and commercialization. Additionally, heightened attention to procurement resilience is catalyzing investments in supplier qualification, strategic inventory buffering, and contractual safeguards that reduce the risk of price shocks. Taken together, the cumulative implications of tariff shifts in 2025 underscore the need for proactive supply chain redesign, scenario planning, and a more deliberate alignment of commercial cadence with manufacturing strategy.

Comprehensive segmentation-driven insight linking product type distinctions, application pathways, and end user configurations to evidence needs, formulation imperatives, and route-to-market choices

Understanding segmentation is essential to designing product portfolios and commercialization pathways that align with customer needs and technical feasibility. When products are viewed through the lens of product type, a primary distinction emerges between naturally derived peptides and synthetic peptides, with synthetic variants further differentiated by chain length into long chain, medium chain, and short chain classes that carry distinct stability, potency, and manufacturing implications. These product-level attributes influence formulation choices, route of administration, and cost structures, and they guide where firms should focus process development and analytical characterization efforts.

Viewing the landscape by application reveals divergent evidence requirements and adoption curves. Growth promotion approaches prioritize compatibility with feed systems and predictable performance under production conditions, whereas prophylactic uses, which include disease prevention strategies and vaccination adjuvants, demand strong safety profiles and clear benefits to herd immunity or disease incidence reduction. Therapeutic applications break down into infection treatment and skin disease treatment, each needing controlled clinical evaluation and dosing strategies that accommodate variability in species, age, and health status. The interplay between application demands and product attributes determines clinical trial design, regulatory pathway selection, and the nature of claims that can be pursued.

End user segmentation highlights operational and commercialization differences across aquaculture farms, feed manufacturers, research institutes, and veterinary clinics. Feed manufacturers must reconcile compatibility with aquafeed and livestock feed formats, focusing on processing stability and uniformity of dosing, while research institutes-which span academic institutes and biotech companies-drive early-stage discovery, mechanism elucidation, and translational studies. Veterinary clinics differentiate between large animal practice and small animal practice needs, which affects dosage forms, administration routes, and practitioner training requirements. These cross-cutting segmentation dimensions underscore that product development and commercialization cannot be one-size-fits-all; instead, they require tailored evidence packages, formulation strategies, and go-to-market models calibrated to each segment's technical constraints and decision drivers.

Regional commercialization and regulatory perspectives across the Americas, Europe Middle East and Africa, and Asia-Pacific that frame differential adoption paths and strategic priorities

Regional dynamics materially shape regulatory strategy, commercialization timing, and investment priorities across the animal antibacterial peptide domain. In the Americas, regulatory bodies and industry stakeholders emphasize antimicrobial stewardship and measurable reductions in antibiotic reliance, creating an environment where demonstrable animal health outcomes and economic justification influence purchasing decisions. This region's strong presence of multinational animal health companies and established contract manufacturing networks supports rapid scale-up for candidates that clear regulatory and clinical thresholds, but it also intensifies competition for veterinarian and producer attention.

In Europe, the Middle East and Africa, regulatory frameworks tend to be heterogeneous, with European jurisdictions often setting higher bars for safety and environmental impact while other countries within the broader region may prioritize access and affordability. Manufacturers seeking to operate across these territories must reconcile disparate approval pathways and data expectations, designing evidence generation strategies that anticipate the most rigorous regulatory requirements while remaining adaptable to local commercial conditions. The Asia-Pacific region presents a different set of dynamics: rapid growth in aquaculture and intensive livestock production creates significant demand for alternatives to conventional antibiotics, and regulatory modernization in several markets is opening pathways for novel interventions. However, the Asia-Pacific landscape also emphasizes cost competitiveness and supply chain proximity, so organizations must weigh pricing strategies and local manufacturing partnerships to gain traction. Across all regions, success depends on aligning scientific validation with pragmatic commercialization approaches that respect local regulatory nuance and customer economics.

Competitive and corporate innovation intelligence showing how incumbents, biotech innovators, and manufacturing specialists collaborate to advance peptide candidates and commercial readiness

The competitive environment for animal antibacterial peptides is characterized by a mix of established animal health companies, emerging biotech players, specialized peptide developers, and contract manufacturing organizations that together create a complex innovation ecosystem. Incumbent animal health firms bring strengths in regulatory navigation, distribution networks, and customer relationships, enabling them to integrate peptide-based products into existing portfolios where evidence supports clinical and economic value. Conversely, smaller biotechnology companies and academic spinouts frequently drive early-stage innovation, advancing novel sequences, delivery platforms, and mechanism-of-action insights that disrupt conventional approaches.

Strategic partnerships and licensing arrangements are common mechanisms to bridge capability gaps and accelerate commercialization. Larger companies may form research collaborations or co-development agreements with peptide specialists to access proprietary chemistries and scalable synthesis methods, while contract development and manufacturing organizations play a pivotal role in moving candidates from bench to GMP-compliant production. Investors and corporate development teams are increasingly attentive to companies that demonstrate clear translational pathways, reproducible manufacturing processes, and defensible intellectual property around peptide sequences and formulations. Competitive differentiation frequently rests on a combination of strong clinical evidence, manufacturing robustness, and the ability to deliver practical administration formats that fit into existing animal health workflows.

Actionable strategic recommendations for industry leaders to accelerate evidence generation, secure resilient supply chains, engage regulators early, and design end user-centric commercialization strategies

Industry leaders should execute a set of prioritized actions to accelerate responsible adoption and capture first-mover advantages while managing technical and commercial risk. First, invest in rigorous, outcome-focused evidence generation that pairs controlled clinical studies with real-world production trials; this dual approach demonstrates both efficacy under ideal conditions and practical benefits under operational realities. Second, develop modular manufacturing strategies that combine in-house capabilities for critical quality attributes with qualified contract partners to provide scale and redundancy, thereby mitigating supply risk and tariff-related disruptions.

Third, build regulatory engagement plans early in development to align study designs with the most stringent expected requirements and to accelerate approvals across multiple jurisdictions. Fourth, design product formats and distribution models that minimize disruption to end users' existing workflows by emphasizing feed-compatible formulations, easy-to-administer dosing systems, and clear guidance for practitioners. Fifth, pursue strategic alliances that couple proprietary peptide technologies with distribution channels and formulation expertise, enabling faster market entry and broader adoption. Implementing these recommendations requires cross-functional governance, disciplined portfolio prioritization, and a willingness to pilot innovative commercial models that reflect the nuanced needs of different end users.

Transparent research methodology combining structured stakeholder interviews, technical literature review, regulatory analysis, and cross-source validation to ensure robust and actionable conclusions

This analysis synthesizes primary and secondary research, technical literature review, and stakeholder engagement to construct an evidence-based perspective on animal antibacterial peptides. Primary inputs included structured interviews with veterinarians, feed formulators, contract manufacturers, and research scientists to ground technical claims in operational realities and to identify adoption barriers encountered in field settings. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and patent filings to map technological trajectories and intellectual property themes, while careful screening avoided relying on single-source commercial summaries.

Analytical methods combined qualitative thematic analysis of interview data with comparative evaluation of regulatory frameworks across jurisdictions to highlight cross-market differences in evidence expectations. Validation occurred through triangulation across data sources and follow-up consultations with subject-matter experts to test assumptions and refine interpretations. The approach emphasized transparency in assumptions, conservative interpretation of experimental results, and clear delineation between established facts and emerging hypotheses. Wherever possible, conclusions reflect consensus views rooted in reproducible methods and corroborating technical literature, ensuring that recommendations are actionable and aligned with current scientific and regulatory realities.

Concluding synthesis that integrates technical promise, commercialization realities, and strategic pathways to guide adoption and investment decisions in animal antibacterial peptides

In conclusion, animal antibacterial peptides represent a promising and pragmatic element of a broader strategy to reduce reliance on traditional antibiotics while improving animal health outcomes and production sustainability. Scientific advances in peptide design and delivery, coupled with evolving regulatory openness to alternatives, have improved the viability of peptide-based interventions. Nonetheless, successful commercialization depends on rigorous evidence of safety and efficacy, manufacturing scalability, and the ability to fit into existing operational models across diverse end users. Organizations that integrate cross-functional capabilities, pursue strategic partnerships, and adopt deliberate supply chain and regulatory strategies will be best positioned to translate scientific potential into commercial impact.

Looking ahead, the path to widespread adoption will be incremental and evidence-driven. Early successes will likely focus on niches where peptides clearly outperform alternatives, such as targeted prophylactic applications or skin disease treatments where topical or localized delivery reduces systemic exposure. Broader adoption will follow as cost-effective manufacturing and robust clinical datasets accumulate. For stakeholders that balance scientific rigor with pragmatic commercialization planning, peptides offer a credible route to meeting stewardship goals while preserving productivity and animal welfare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibacterial Peptide Market, by Product Type

  • 8.1. Naturally Derived Peptide
  • 8.2. Synthetic Peptide
    • 8.2.1. Long Chain
    • 8.2.2. Medium Chain
    • 8.2.3. Short Chain

9. Animal Antibacterial Peptide Market, by Application

  • 9.1. Growth Promotion
  • 9.2. Prophylactic
    • 9.2.1. Disease Prevention
    • 9.2.2. Vaccination Adjuvant
  • 9.3. Therapeutic
    • 9.3.1. Infection Treatment
    • 9.3.2. Skin Disease Treatment

10. Animal Antibacterial Peptide Market, by End User

  • 10.1. Aquaculture Farms
  • 10.2. Feed Manufacturers
    • 10.2.1. Aquafeed
    • 10.2.2. Livestock Feed
  • 10.3. Research Institutes
    • 10.3.1. Academic Institute
    • 10.3.2. Biotech Company
  • 10.4. Veterinary Clinics
    • 10.4.1. Large Animal Practice
    • 10.4.2. Small Animal Practice

11. Animal Antibacterial Peptide Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Animal Antibacterial Peptide Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Animal Antibacterial Peptide Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Animal Antibacterial Peptide Market

15. China Animal Antibacterial Peptide Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AB Vista Limited
  • 16.6. AgroBioTek Laboratories LLC
  • 16.7. Animal Medics
  • 16.8. Anitox Corporation
  • 16.9. Biogenesis Bago S.A.
  • 16.10. Biosynth Ltd
  • 16.11. Boehringer Ingelheim International GmbH
  • 16.12. Cargill, Incorporated
  • 16.13. Dechra Pharmaceuticals PLC
  • 16.14. Eco Animal Health Ltd.
  • 16.15. Elanco Animal Health Incorporated
  • 16.16. Esco Aster Pte. Ltd.
  • 16.17. Genera Inc.
  • 16.18. Huvepharma S.A.
  • 16.19. ImmuCell Corporation
  • 16.20. Kemin Industries, Inc.
  • 16.21. Merck & Co., Inc.
  • 16.22. Neogen Corporation
  • 16.23. Novozymes A/S
  • 16.24. Phibro Animal Health Corporation
  • 16.25. Vetbiochem India Pvt Ltd.
  • 16.26. Vetoquinol S.A.
  • 16.27. Zoetis Inc.
  • 16.28. Zomedica Pharmaceuticals Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY NATURALLY DERIVED PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LONG CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY MEDIUM CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHORT CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROWTH PROMOTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VACCINATION ADJUVANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY INFECTION TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SKIN DISEASE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUACULTURE FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY AQUAFEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LIVESTOCK FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ACADEMIC INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY BIOTECH COMPANY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LARGE ANIMAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SMALL ANIMAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SYNTHETIC PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PROPHYLACTIC, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY FEED MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY VETERINARY CLINICS, 2018-2032 (USD MILLION)